Hematology

February 4th 2026

Real-world inotuzumab ozogamicin boosts remission in relapsed/refractory B-cell ALL, supports transplant, and flags sinusoidal obstruction syndrome risk.

January 29th 2026

Disparities in access to allo-HCT for AML persist, highlighting the need for targeted interventions to ensure equitable treatment for all patients.

January 28th 2026

This new study reveals venetoclax and rituximab effectively treat chronic lymphocytic leukemia, showing high response rates and prolonged progression-free survival.

January 27th 2026

This approval brings the total indications for daratumumab and hyaluronidase to 5 in newly diagnosed disease and its 12th overall.